Novartis: cancer drug Zykadia gets use expansion.
(CercleFinance.com) - Swiss drugmaker Novartis has received approval from the European Commission to expand the use of Zykadia to ALK-positive advanced non-small cell lung cancer (NSCLC).
The approval follows a positive opinion granted in May by the Committee for Medicinal Products for Human Use (CHMP), and is applicable to all 28 European Union member states plus Iceland, Lichtenstein, and Norway.
Novartis said the first-line approval of Zykadia is based on results from a phase III trial which demonstrated a 45% reduction in the risk of disease progression in the Zykadia arm compared to chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The approval follows a positive opinion granted in May by the Committee for Medicinal Products for Human Use (CHMP), and is applicable to all 28 European Union member states plus Iceland, Lichtenstein, and Norway.
Novartis said the first-line approval of Zykadia is based on results from a phase III trial which demonstrated a 45% reduction in the risk of disease progression in the Zykadia arm compared to chemotherapy.
Copyright (c) 2017 CercleFinance.com. All rights reserved.